Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Sorafenib Versus Placebo in Addition to Standard Therapy in Adult Patients ≥60 Years with Newly Diagnosed Acute Myeloid Leukemia: Results From the Randomized-Controlled Soraml Trial

Blood (2012) 120 (21): 144.

https://doi.org/10.1182/blood.V120.21.144.144

Published: 2012

Journal Articles

Aurora-A Polymorphisms in Multiple Myeloma: Implications On Chromosomal Instability

Ludmila Weiz, Suzin Choi, PhD, Niels Weinhold, PhD, Kai Neben, MD, Anthony D Ho, MD, Hartmut Goldschmidt, MD, PhD, Kari Hemminki, PhD, Alwin Krämer, MD, Marc S Raab, MD

Blood (2012) 120 (21): 3982.

https://doi.org/10.1182/blood.V120.21.3982.3982

Published: 2012

Journal Articles

Phase I/II Study of Volasertib (BI 6727), an Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Results From the Randomized Phase II Part for Volasertib in Combination with Low-Dose Cytarabine (LDAC) Versus LDAC Monotherapy in Patients with Previously Untreated AML Ineligible for Intensive Treatment

Johan Maertens, MD, PhD, Michael Lübbert, MD, Walter Fiedler, MD, Loic Fouillard, Alf Haaland, MD, Joseph M. Brandwein, MD, Stéphane Lepretre, MD, Oumédaly Reman, MD, Pascal Turlure, MD, Gesine Bug, Carsten Müller-Tidow, Alwin Krämer, MD, Florian Voss, PhD, Tillmann Taube, MD, Holger Fritsch, PhD, Hartmut Döhner, MD

Blood (2012) 120 (21): 411.

https://doi.org/10.1182/blood.V120.21.411.411

Published: 2012

Journal Articles

No Benefit of Combining Additional Compounds with Standard High Dose Cytarabine Consolidation: Results of the Prospective Randomized AML2003 Study

Blood (2011) 118 (21): 255.

https://doi.org/10.1182/blood.V118.21.255.255

Published: 2011

Journal Articles

Deregulated EVI1 Expression Leads to Genomic Instability and G1 Cell Cycle Arrest

Friederike Herbst, Claudia R Ball, PhD, Wei Wang, Kadin Karakaya, Sylvia Fessler, Alwin Krämer, MD, Manfred Schmidt, PhD, Christof von Kalle, MD, Hanno Glimm, MD

Blood (2011) 118 (21): 2431.

https://doi.org/10.1182/blood.V118.21.2431.2431

Published: 2011

Journal Articles

Rituximab Maintenance Therapy in Diffuse Large B-Cell Lymphoma in a Multicenter Prospective Randomised Phase II Study,

Mathias Witzens-Harig, MD, Axel Benner, Michael Rieger, MD, Fabienne McClanahan, MD, Manfred Hensel, MD, Kai Neben, MD, Peter Dreger, MD, Eva Lengfelder, MD, Ingo Schmidt-Wolf, MD, Alwin Krämer, MD, PhD, Anthony D. Ho, MD

Blood (2011) 118 (21): 3700.

https://doi.org/10.1182/blood.V118.21.3700.3700

Published: 2011

Journal Articles

Survivin in Multiple Myeloma: Prognostic and Therapeutic Implications

Verena Wagner, Dirk Hose, MD, Anja Seckinger, Ludmila Weitz, MSc, Tobias Meißner, Thierry Reme, Jean-Francois Rossi, MD, PhD, Hartmut Goldschmidt, MD, Alwin Krämer, MD, Bernard Klein, Marc S Raab, MD

Blood (2011) 118 (21): 137.

https://doi.org/10.1182/blood.V118.21.137.137

Published: 2011

Journal Articles

Phase I/II Study of Volasertib (BI 6727), An Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Updated Results of the Dose Finding Phase I Part for Volasertib in Combination with Low-Dose Cytarabine (LD-Ara-C) and As Monotherapy in Relapsed/Refractory AML

Gesine Bug, MD, Carsten Müller-Tidow, MD, Richard F Schlenk, MD, Alwin Krämer, MD, Michael Lübbert, MD, PhD, Utz Krug, MD, Florian Voss, PhD, Tillmann Taube, MD, Holger Fritsch, PhD, Pilar Garin-Chesa, MD, PhD, Oliver G Ottmann, MD, Hartmut Döhner, MD

Blood (2011) 118 (21): 1549.

https://doi.org/10.1182/blood.V118.21.1549.1549

Published: 2011

Journal Articles

Phase I/II Study of BI 6727 (volasertib), An Intravenous Polo-Like Kinase-1 (Plk1) Inhibitor, In Patients with Acute Myeloid Leukemia (AML): Results of the Dose Finding for BI 6727 In Combination with Low-Dose Cytarabine

Gesine Bug, MD, PhD, Richard F. Schlenk, MD, PhD, Carsten Müller-Tidow, MD, PhD, Michael Lübbert, MD, PhD, Alwin Krämer, MD, PhD, Frank Fleischer, Tillmann Taube, MD, Oliver G. Ottmann, MD, PhD, Hartmut Doehner, MD, PhD

Blood (2010) 116 (21): 3316.

https://doi.org/10.1182/blood.V116.21.3316.3316

Published: 2010

Journal Articles

Sorafenib In Combination with Standard Induction and Consolidation Therapy In Elderly AML Patients: Results From a Randomized, Placebo-Controlled Phase II Trial

Blood (2010) 116 (21): 333.

https://doi.org/10.1182/blood.V116.21.333.333

Published: 2010

Journal Articles

Phase I/II Study of BI 2536, An Intravenous Polo-Like Kinase-1 (Plk-1) Inhibitor, in Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): First Results of a Multi-Center Trial

C. Müller-Tidow, MD, Gesine Bug, MD, Richard Schlenk, MD, Michael Lübbert, MD, PhD, Alwin Krämer, MD, Juergen Krauter, MD, David Nachbaur, MD, Peter Valent, MD, Tillmann Taube, MD, Gerd Munzert, MD, Kang-Hun Lee, MD, Hartmut Dohner, MD

Blood (2008) 112 (11): 2973.

https://doi.org/10.1182/blood.V112.11.2973.2973

Published: 2008

Journal Articles

High-Dose Therapy with Peripheral Blood Stem Cell Transplantation for Patients with Relapsed or Refractory Hodgkin’s Disease: A Single-Institution 20-Year Follow-up Experience.

Kai Neben, MD, Julia Meissner, MD, Sascha Dietrich, MD, Manfred Hensel, MD, Alwin Krämer, MD, Mathias Witzens-Harig, MD, Peter Dreger, MD, Anthony D. Ho, MD

Blood (2008) 112 (11): 2145.

https://doi.org/10.1182/blood.V112.11.2145.2145

Published: 2008

Journal Articles

Chromosomal Instability Correlates with Poor Outcome in Patients with Myelodysplastic Syndromes

Christoph E. Heilig, Harald Löffler, Anna Jauch, Ulrich Mahlknecht, Anthony Ho, Alwin Krämer

Blood (2008) 112 (11): 5077.

https://doi.org/10.1182/blood.V112.11.5077.5077

Published: 2008

Journal Articles

Inhibition of Aurora-Kinases for Tailored Risk-Adapted Treatment of Multiple Myeloma

Blood (2008) 112 (11): 248.

https://doi.org/10.1182/blood.V112.11.248.248

Published: 2008

Journal Articles

Rituximab Maintenenance Therapy in CD20+ B-Cell Non-Hodgkin-Lymphoma - Results of a Multicenter Prospective Randomised Phase II Study.

Mathias Witzens-Harig, MD, Manfred Hensel, MD, Johann W. Schmier, MD, Kai Neben, MD, Axel Benner, PhD, Peter Dreger, MD, Christian Kuhn, MD, Ingo Schmidt-Wolf, MD, Alwin Krämer, MD, Anthony D. Ho, MD

Blood (2006) 108 (11): 4704.

https://doi.org/10.1182/blood.V108.11.4704.4704

Published: 2006

Journal Articles

Centrosome aberrations in acute myeloid leukemia are correlated with cytogenetic risk profile

Kai Neben, Christian Giesecke, Silja Schweizer, Anthony D. Ho, Alwin Krämer

Blood (2003) 101 (1): 289–291.

https://doi.org/10.1182/blood-2002-04-1188

Published: 2003

Journal Articles

Reduced risk for chronic myelogenous leukemia in individuals with the cytochrome P-450 gene polymorphism CYP1A1*2A

Harald Löffler, Jörg Bergmann, Andreas Hochhaus, Rüdiger Hehlmann, Alwin Krämer, the German CML Study Group

Blood (2001) 98 (13): 3874–3875.

https://doi.org/10.1182/blood.V98.13.3874

Published: 2001

NARROW

Sorafenib Versus Placebo in Addition to Standard Therapy in Adult Patients ≥60 Years with Newly Diagnosed Acute Myeloid Leukemia: Results From the Randomized-Controlled Soraml Trial

Aurora-A Polymorphisms in Multiple Myeloma: Implications On Chromosomal Instability

No Benefit of Combining Additional Compounds with Standard High Dose Cytarabine Consolidation: Results of the Prospective Randomized AML2003 Study

Deregulated EVI1 Expression Leads to Genomic Instability and G1 Cell Cycle Arrest

Rituximab Maintenance Therapy in Diffuse Large B-Cell Lymphoma in a Multicenter Prospective Randomised Phase II Study,

Survivin in Multiple Myeloma: Prognostic and Therapeutic Implications

Phase I/II Study of Volasertib (BI 6727), An Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Updated Results of the Dose Finding Phase I Part for Volasertib in Combination with Low-Dose Cytarabine (LD-Ara-C) and As Monotherapy in Relapsed/Refractory AML

Phase I/II Study of BI 6727 (volasertib), An Intravenous Polo-Like Kinase-1 (Plk1) Inhibitor, In Patients with Acute Myeloid Leukemia (AML): Results of the Dose Finding for BI 6727 In Combination with Low-Dose Cytarabine

Sorafenib In Combination with Standard Induction and Consolidation Therapy In Elderly AML Patients: Results From a Randomized, Placebo-Controlled Phase II Trial

Phase I/II Study of BI 2536, An Intravenous Polo-Like Kinase-1 (Plk-1) Inhibitor, in Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): First Results of a Multi-Center Trial

High-Dose Therapy with Peripheral Blood Stem Cell Transplantation for Patients with Relapsed or Refractory Hodgkin’s Disease: A Single-Institution 20-Year Follow-up Experience.

Chromosomal Instability Correlates with Poor Outcome in Patients with Myelodysplastic Syndromes

Inhibition of Aurora-Kinases for Tailored Risk-Adapted Treatment of Multiple Myeloma

Rituximab Maintenenance Therapy in CD20+ B-Cell Non-Hodgkin-Lymphoma - Results of a Multicenter Prospective Randomised Phase II Study.

Centrosome aberrations in acute myeloid leukemia are correlated with cytogenetic risk profile

Reduced risk for chronic myelogenous leukemia in individuals with the cytochrome P-450 gene polymorphism CYP1A1*2A

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only